Indero Marks 40th Study Live with Veeva RTSM

Rhea-AI Summary

Veeva Systems (NYSE: VEEV) announced that Indero, formerly Innovaderm Research, has successfully completed its 40th study implementation using Veeva RTSM (Randomization and Trial Supply Management). This milestone demonstrates the successful standardization of Indero's clinical trial operations using Veeva's RTSM platform.

The specialized CRO has leveraged Veeva RTSM's advanced capabilities to enhance operational efficiency, improve process consistency, and streamline trial execution. Eric Hardy, senior director of biometrics at Indero, highlighted that the platform has enabled more efficient processes and better collaboration, ultimately accelerating the path to bringing therapies to market.

The partnership between Indero and Veeva has focused on developing and implementing standardized processes for long-term clinical trial success, with Veeva's enterprise standard RTSM approach contributing to greater efficiency and reliability in study execution.

Positive

• Milestone achievement of 40 successful RTSM study implementations
• Enhanced operational efficiency and faster study timelines
• Successful standardization of clinical trial processes

Negative

• None.

News Market Reaction

+0.31%

1 alert

+0.31% News Effect

On the day this news was published, VEEV gained 0.31%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Specialized CRO standardizes on Veeva RTSM to drive operational efficiency and faster study timelines

PLEASANTON, Calif., March 19, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Indero, formerly Innovaderm Research, successfully launched its 40th RTSM study on Veeva RTSM. By standardizing with Veeva RTSM, Indero has strengthened its clinical trial operations, harnessing advanced RTSM capabilities and expert support to drive efficiency, enhance process consistency, and streamline execution.

"As we continue to optimize our clinical trial operations, Veeva RTSM has driven more efficient processes and closer collaboration to ensure seamless execution," said Eric Hardy, senior director, biometrics at Indero. "Because of this added speed and effectiveness, we can help bring therapies to market faster, allowing our sponsors, sites, and patients to benefit sooner."

The launch of Indero's 40th RTSM study highlights the continued collaboration between the two organizations. Since first adopting Veeva RTSM, Indero has worked closely with Veeva to continuously refine and implement standardized processes that drive long-term success for its clinical trials.

"With its enterprise standard RTSM approach, Indero is achieving greater long-term efficiency and reliability in their studies," said Steve Simmerman, general manager, Veeva RTSM. "Partnering with Indero to standardize clinical processes will further accelerate study timelines, demonstrating a streamlined approach that can advance the industry."

Additional Information
To learn more about Veeva's enterprise standard RTSM, visit www.veeva.com/rtsm.

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/indero-marks-40th-study-live-with-veeva-rtsm-302405321.html

SOURCE Veeva Systems

FAQ

How many RTSM studies has Indero completed using Veeva's platform?

Indero has successfully launched 40 RTSM studies using Veeva's platform.

What benefits has Indero gained from standardizing with Veeva RTSM?

Indero has achieved enhanced operational efficiency, improved process consistency, streamlined execution, and faster study timelines.

How does Veeva RTSM (VEEV) impact clinical trial timelines?

Veeva RTSM accelerates study timelines through standardized processes and improved collaboration, helping bring therapies to market faster.

What is the strategic importance of Indero's partnership with Veeva RTSM?

The partnership focuses on implementing standardized processes for long-term clinical trial success, driving greater efficiency and reliability in study execution.